Cyclophosphamide: Effective in the treatment of severe cutaneous involvement in systemic sclerosis

Revista Brasileira de Reumatologia

Volumn 49, Issue 3, 2009, Pages 270-275

  de Macedo, Patricia Andrade ^a   Borges, Cláudia Teresa Lobato ^a   de Souza, Romy Beatriz Christmann ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclophosphamide; Modified Rodnan skin score; Systemic sclerosis; Treatment

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MALE; OUTCOME ASSESSMENT; SCORING SYSTEM; SEX RATIO; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; URINARY TRACT DISEASE;

EID: 67651173119     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20(11):1892-6.
2. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25(1):84-8.
3. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33(8):1256-63.
4. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44(12):2828-35.
5. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43(11):2437-44.
6. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
7. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al. Predictors and outcomes of scleroderma renal crisis: the High-Dose Versus Low-Dose D-Penicillamine in Early Diffuse Systemic Sclerosis Trial. Arthritis Rheum 2002;46:2983-9.
8. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM et al. Relationship between Change in Skin Score and Disease Outcome in Diffuse Cutaneous Systemic Sclerosis. Application of a Latent Linear Trajectory Model. Arthritis Rheum 2007;56(7):2422-2431.
9. Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol 2007;46(2):218-23.
10. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44(6):1351-8.
11. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006;25(2):205-12.
12. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25):2655-66.
13. Valentini G, Paone C, La Montagna G, Chiarolanza I, Menegozzo M, Colutta E et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006;35(1):35-8.
14. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176(10):1026-34.
15. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581-90.
16. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Ozturk MA 16. et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003;22:289-94.
17. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD et al. Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum 2007;56(5):1676-84.
18. DAngelo S, Cuomo G, Paone C, Coluta E, La Montagna G, Valentini G. Low-dose intravenous cyclophosphamide in systemic sclerosis: a preliminary safety study. Clin Rheumatol 2003;22:393-6.